BALA CYNWYD, PA--(MARKET WIRE)--Oct 11, 2007 -- Duska Therapeutics, Inc. ("Duska" or the "Company") (OTC BB:DSKA.OB - News), a biopharmaceutical company developing new medicines to treat cardiovascular diseases, announced today the appointment of H. David Coherd to the board of directors. Mr. Coherd is a co-founder and Managing Director of Growth Capital Partners, LLC, an investment banking firm. He oversees public and private healthcare for the firm. He is also the managing member of BioMed Cap, LLC, a firm focused on life science investing.

Mr. Coherd is a business leader with over 17 years' experience in investment banking with a major focus in life sciences and healthcare. He has co-founded three successful investment banking firms: Perpetual Growth Advisors, LLC, Cardinal Securities, LLC and most recently, Growth Capital Partners, LLC. During his career, he has been actively involved in sourcing, structuring, and closing over 55 PIPE Transactions. Previously, Mr. Coherd was a Vice-President at Josephthal & Co. and JW Charles Securities, where he was involved in over 25 IPOs in life sciences and other areas. He graduated cum laude from Georgia State University with a BBA in Economics.

Dr. James Kuo, Duska's Chairman and CEO, stated, "We are fortunate to have someone of Mr. Coherd's extensive financial experience and expertise join our board at this exciting time in the company's history. His in-depth knowledge of life science financing and healthcare will certainly be an asset to the Company and facilitate its growth."

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc., based in Bala Cynwyd, Pennsylvania, develops new medicines to treat cardiovascular diseases by modulating the P2 receptor in the heart and lungs. In addition to ATPace™ (adenosine triphosphate injection) for the treatment and diagnosis of certain cardiac arrhythmias, Duska has drug development programs targeting chronic obstructive pulmonary disorders and cough, male infertility and mitigating the toxic effects of radiation exposure. For more information, visit Duska's website: www.duskatherapeutics.com.

Forward-Looking Statement: This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and certainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the early stage of Duska's drug development projects, Duska's limited financial resources and its need to raise additional capital to fund its ongoing working capital and drug development needs, the need for future clinical testing of Duska's drug candidates, uncertainties regarding the scope of the clinical testing that may be required by regulatory authorities and the outcomes of those tests, the significant time and expense that will be incurred in developing any of the potential commercial applications for Duska's P2R technologies, risks relating to the enforceability of any patents covering Duska's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for Duska's products. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. All forward-looking statements are based upon information available to Duska on the date the statements are first published. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

     Contact:
     Duska Therapeutics, Inc.
     General Information
     Wayne Lorgus
     Chief Financial Officer
     (610) 660-6690